Site icon Press Network of India

Cancer Immunotherapy: Who is Most Likely to Benefit?

By  Dr Peush Bajpai, Senior Director & Unit Head Medical Oncology, Max Super Speciality Hospital, Dwarka

“Can I get immunotherapy?” It is one of the first questions people ask after a cancer diagnosis. The answer can differ even for two people with cancer in the same organ. Immunotherapy has improved outcomes in several cancers, and choosing the right drug for the right patient matters. Oncologists consider the exact type and stage of cancer, the tumor test results, and the patient’s general health and medical history.

How immunotherapy takes the brakes off

The immune system has natural brakes that protect healthy tissues. Some cancers deactivate or put the brakes on Immune cells with certain signals. Drugs called checkpoint inhibitors block these signals, allowing immune cells to attack the cancer. For some people with advanced disease, that can mean years of cancer control. In others, the cancer may stay stable for a time or continue to grow despite treatment.

Who is most likely to benefit?

Immunotherapy has a role in selected lung, kidney, bladder, and head and neck cancers, as well as melanoma, a type of skin cancer. It is also used for some people with triple-negative breast cancer, which can grow and spread faster than some other breast cancer subtypes.

In selected cancers that can be removed surgically, such as certain lung cancers and high-risk early triple-negative breast cancer, studies have shown benefits from starting immunotherapy before surgery as part of a planned course. Doctors call this as neoadjuvant treatment. Depending on the cancer, immunotherapy may be combined with chemotherapy and may continue after surgery.

The goal of treatment also matters. Before surgery, the aim may be to shrink the tumor and reduce the chance that the cancer comes back. When cancer has spread, the aim is often to keep it under control for as long as possible. Scans help assess whether treatment is working over the following months.

What can tumor tests tell us?

In some cancers, measuring PD-L1 (Programmed Cell Death Protein 1) helps doctors decide whether to use immunotherapy and whether to give it alone or with another treatment. Other tests look for faulty DNA repair, reported as deficient mismatch repair (dMMR) or high microsatellite instability (MSI-H). This finding can make immunotherapy a particularly valuable option in some bowel cancers. It can also prompt further testing for an inherited condition called Lynch syndrome.

Genomic testing can measure tumor mutational burden (TMB), an estimate of how many DNA changes a tumor carries. A high result can help guide treatment in selected advanced cancers. The meaning of each result depends on the cancer and the treatment being considered.

What should patients watch for?

Fatigue or a mild rash can occur. Checkpoint inhibitors can also cause more serious inflammation in healthy organs, such as the lungs, bowel or thyroid. Blood tests before and during treatment can pick up changes in thyroid, liver or kidney function. Report new breathlessness or persistent diarrhoea promptly, even after treatment has ended. Many side effects can be managed when caught early, although some, such as thyroid problems, may need long-term treatment.

Before starting treatment, tell your oncologist if you have an autoimmune condition or have had an organ transplant. This history can change the balance of benefits and risks. Ask what your follow-up will involve, who will review your blood test results and how to reach the team if symptoms appear between visits.

Key take-home points

·       Ask how much benefit immunotherapy offers for your exact cancer type and stage.

·       Ask which tumor tests could change your treatment plan and when immunotherapy would fit into it.

·       Know which symptoms to report and whom to call if they develop.

****

Exit mobile version